16-1202303-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4BS1BS2
The NM_021098.3(CACNA1H):c.1853C>T(p.Pro618Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000919 in 1,585,064 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00048 ( 1 hom., cov: 34)
Exomes 𝑓: 0.00097 ( 2 hom. )
Consequence
CACNA1H
NM_021098.3 missense
NM_021098.3 missense
Scores
3
12
4
Clinical Significance
Conservation
PhyloP100: 3.46
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -9 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.34770316).
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000479 (73/152304) while in subpopulation NFE AF= 0.000809 (55/68006). AF 95% confidence interval is 0.000638. There are 1 homozygotes in gnomad4. There are 37 alleles in male gnomad4 subpopulation. Median coverage is 34. This position pass quality control queck.
BS2
High AC in GnomAd4 at 73 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1H | NM_021098.3 | c.1853C>T | p.Pro618Leu | missense_variant | 9/35 | ENST00000348261.11 | NP_066921.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1H | ENST00000348261.11 | c.1853C>T | p.Pro618Leu | missense_variant | 9/35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
CACNA1H | ENST00000565831.6 | c.1853C>T | p.Pro618Leu | missense_variant | 8/33 | 1 | ENSP00000455840.1 | |||
CACNA1H | ENST00000638323.1 | c.1814C>T | p.Pro605Leu | missense_variant | 9/35 | 5 | ENSP00000492267.1 | |||
CACNA1H | ENST00000639478.1 | n.1853C>T | non_coding_transcript_exon_variant | 9/35 | 5 | ENSP00000491945.1 | ||||
CACNA1H | ENST00000640028.1 | n.1385+468C>T | intron_variant | 5 | ENSP00000491488.1 |
Frequencies
GnomAD3 genomes AF: 0.000480 AC: 73AN: 152186Hom.: 1 Cov.: 34
GnomAD3 genomes
AF:
AC:
73
AN:
152186
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000536 AC: 105AN: 196016Hom.: 0 AF XY: 0.000493 AC XY: 53AN XY: 107556
GnomAD3 exomes
AF:
AC:
105
AN:
196016
Hom.:
AF XY:
AC XY:
53
AN XY:
107556
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000966 AC: 1384AN: 1432760Hom.: 2 Cov.: 57 AF XY: 0.000970 AC XY: 689AN XY: 710164
GnomAD4 exome
AF:
AC:
1384
AN:
1432760
Hom.:
Cov.:
57
AF XY:
AC XY:
689
AN XY:
710164
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000479 AC: 73AN: 152304Hom.: 1 Cov.: 34 AF XY: 0.000497 AC XY: 37AN XY: 74472
GnomAD4 genome
AF:
AC:
73
AN:
152304
Hom.:
Cov.:
34
AF XY:
AC XY:
37
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
4
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
4
ExAC
AF:
AC:
62
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:3Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:1Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 06, 2015 | The P618L variant in the CACNA1H gene has been reported previously in association with familial cases of epilepsy; however, this variant did not segregate with the disease in all families reported (Heron et al., 2004; Heron et al., 2007). The P618L variant was not observed with any significant frequency in approximately 5,900 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. The P618L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. Functional characterization of P618L indicates that this variant results in accelerated channel activation as well as channel inactivation, thereby allowing for greater channel availability of P618L compared to wild type (Khosravani et al., 2005). We interpret P618L as a variant of unknown significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 14, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2021 | - - |
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | - - |
Epilepsy, idiopathic generalized, susceptibility to, 6 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | May 01, 2005 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
T;.;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;.
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;M;M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.;D;D
REVEL
Uncertain
Sift
Uncertain
D;.;D;D
Sift4G
Benign
T;.;T;T
Polyphen
P;.;D;D
Vest4
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at